Ernexa Therapeutics (NASDAQ:ERNA) Issues Earnings Results

Ernexa Therapeutics (NASDAQ:ERNA) issued its earnings results on Monday. The company reported ($6.95) EPS for the quarter, Zacks reports.

Ernexa Therapeutics Stock Up 78.8%

ERNA stock traded up $5.68 during trading on Tuesday, hitting $12.89. 16,208,268 shares of the company’s stock traded hands, compared to its average volume of 1,075,689. The firm has a market capitalization of $15.08 million, a P/E ratio of -0.17 and a beta of 1.88. Ernexa Therapeutics has a 1 year low of $3.18 and a 1 year high of $100.46. The business has a fifty day simple moving average of $5.89 and a two-hundred day simple moving average of $20.80.

Institutional Trading of Ernexa Therapeutics

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned approximately 0.39% of Ernexa Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 70.55% of the company’s stock.

Analyst Upgrades and Downgrades

ERNA has been the topic of several research analyst reports. Brookline Capital Markets started coverage on Ernexa Therapeutics in a research note on Thursday, May 7th. They issued a “buy” rating and a $30.00 price objective on the stock. Wall Street Zen raised Ernexa Therapeutics to a “hold” rating in a research report on Saturday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ernexa Therapeutics in a report on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $30.00.

Key Ernexa Therapeutics News

Here are the key news stories impacting Ernexa Therapeutics this week:

• Positive Sentiment: Brookline Capital Markets reiterated a Buy rating on Ernexa Therapeutics and maintained a $30 price target, signaling confidence in the company’s longer-term outlook despite recent losses. Brookline Capital Markets earnings estimates for ERNA
• Neutral Sentiment: Ernexa Therapeutics released a virtual investor KOL Connect segment focused on the ovarian cancer landscape and its lead candidate, ERNA-101, which may help keep investor attention on the pipeline. ERNA-101 investor update article
• Negative Sentiment: The company reported a much wider-than-expected quarterly loss of ($6.95) per share, well below the consensus estimate of ($1.95), highlighting ongoing profitability pressure. ERNA earnings miss
• Negative Sentiment: Trading in ERNA was halted multiple times this morning due to LULD pauses, reflecting extreme volatility and rapid price swings that often accompany thinly traded biotech names. ERNA trading halts

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.